Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--
Stay updated with breaking news from Hal Mackins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--
- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics
Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline March 8, 2021 GMT ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Mar 8, 2021-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2021--